Precigen (NASDAQ:PGEN – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Precigen to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of current recommendations for Precigen and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precigen | 1 | 1 | 4 | 0 | 2.50 |
| Precigen Competitors | 9800 | 15082 | 45386 | 1579 | 2.54 |
Precigen currently has a consensus target price of $13.50, suggesting a potential upside of 219.91%. As a group, “Biotechnology” companies have a potential upside of 104.65%. Given Precigen’s higher probable upside, analysts plainly believe Precigen is more favorable than its rivals.
Insider and Institutional Ownership
33.5% of Precigen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Precigen has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Precigen’s rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.
Valuation and Earnings
This table compares Precigen and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Precigen | $9.68 million | -$250.64 million | -4.06 |
| Precigen Competitors | $730.85 million | $13.53 million | -10.85 |
Precigen’s rivals have higher revenue and earnings than Precigen. Precigen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Precigen and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precigen | 15.55% | 86.42% | 15.77% |
| Precigen Competitors | -12,359.35% | -203.09% | -30.93% |
Summary
Precigen beats its rivals on 7 of the 13 factors compared.
Precigen Company Profile
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.
